BIOPHYTIS S.A. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.85 EUR | 0.00% |
|
+1.19% | -58.33% |
| May. 14 | Biophytis unveils design for obesity study | CF |
| May. 14 | Biophytis SA Announces the Design of its Phase 2 OBA Clinical Study in Obesity | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Biophytis S.A. is a biotechnology company in the clinical stage specialized in the development of drug candidates to slow degenerative processes and improve functional capacity in patients with age-related diseases, including respiratory failure in patients suffering from COVID-19.
The company is located in Paris, France and Cambridge, Massachusetts.
Calendar
2024-10-28
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -58.33% | 2.49M | |
| +8.29% | 113B | |
| +10.21% | 106B | |
| +0.41% | 22.27B | |
| -11.90% | 22.22B | |
| -5.99% | 19.43B | |
| -37.36% | 17.87B | |
| -5.17% | 17.24B | |
| +7.70% | 14.29B | |
| +37.65% | 12.52B |
- Stock Market
- Equities
- ALBPS Stock
- ALBPS Stock
- News Biophytis S.A.
- HC Wainwright Reiterates Biophytis at Buy With $15 Price Target